Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations
|
|
- Ashlynn Clark
- 8 years ago
- Views:
Transcription
1 natomic Pathology / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations Dean-Yar Tigrani, MD, and Jamie. Weydert, MD Key Words: Osteopontin; Mesothelioma; Immunohistochemistry DOI: /ME4VG11LDX8KMTN bstract The morphologic distinction of epithelioid mesothelioma from a reactive mesothelial proliferation can be difficult. Recent studies have demonstrated that serum osteopontin levels are increased in patients with mesotheliomas. We sought to determine if osteopontin expression is diagnostically helpful in distinguishing epithelioid mesothelioma from reactive mesothelial proliferations. We studied 7 cases of epithelioid mesothelioma and 20 cases of reactive mesothelial proliferations by immunohistochemical analysis using standard technique. ll 7 mesotheliomas and 19 of 20 reactive mesothelial proliferations showed osteopontin expression. Osteopontin expression is not restricted to malignant mesothelial proliferations, and immunohistochemical analysis for osteopontin is not helpful in determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations. Malignant mesothelioma is a tumor of mesothelial cell origin, which lines serosal surfaces such as the pleural, peritoneal, pericardial, and testicular cavities. Pleural malignant mesotheliomas are strongly associated with previous asbestos exposure. The prognosis for pleural malignant mesotheliomas is poor, with a median survival of less than 12 months after diagnosis. 1,2 Tissue pathology remains the gold standard of diagnosis of mesothelioma. The grave prognosis and medicolegal issues that are engendered by a diagnosis of malignant mesothelioma place pathologists in a critical and often difficult position as a clinical diagnostician. The differentiation of mesothelioma from carcinoma of nonmesothelial origin has been made somewhat easier during the last several years by the development and clinical characterization of immunohistochemical panels. 3 n equally problematic diagnostic dilemma is the differentiation of a malignant mesothelial process from a reactive one. Reactive mesothelial proliferations may show high cellularity, cytologic atypia, necrosis, papillary excrescences, and entrapment ( pseudoinvasion ; benign mesothelial cells entrapped within organizing pleuritis). Conversely, malignant mesotheliomas may appear bland. ncillary studies are of little to no value in this scenario, and the distinction remains a clinicopathologic one, wherein the pathologic parameter is morphologic assessment by standard H&E light microscopy. 4 Osteopontin is a phosphoprotein with a variety of physiologic roles, including anchoring osteoclasts to bone mineral matrix, functioning as a normal component of elastic fibers of skin and aorta, and acting as a protein ligand of CD It has also been shown to be expressed in a variety of carcinomas, including lung, breast, and prostate recent study showed that patients with pleural malignant mesotheliomas 580 m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN
2 natomic Pathology / ORIGINL RTICLE had significantly higher osteopontin levels than those in a noncancer group with a history of asbestos exposure. Expression of osteopontin in pleural malignant mesotheliomas in this cohort was demonstrated by immunohistochemical staining, and lung parenchyma and adjacent normal pleura were reportedly negative. 22 Given the recent findings linking increased serum osteopontin levels and malignant mesothelioma, we sought to determine if immunohistochemical osteopontin expression is diagnostically useful in distinguishing epithelioid mesothelioma from reactive mesothelial proliferations in recent material from our department s case file. Differential expression would suggest that immunohistochemical analysis using the osteopontin antibody may be a useful ancillary study when the distinction is difficult by histomorphologic examination alone. Materials and Methods pproval for this research was granted by our local institutional review board. total of 7 cases of epithelioid mesothelioma (2 autopsy cases, 5 surgical biopsy and resection specimens) and 20 cases of reactive or atypical mesothelial proliferations were studied. These cases were extracted from our departmental files using a retrospective SNOMED (Systematic Nomenclature of Medicine) terminology search in our laboratory information system (CERNER, Kansas City, MO). The diagnostic H&E-stained slides were reviewed from each case, and clinical follow-up was obtained in the cases of reactive or atypical mesothelial processes to ensure that none of the patients developed malignancy of the pleura up to the time of this study. Immunohistochemical studies were also reviewed for accuracy of interpretation in the cases of mesothelioma. Immunohistochemical analysis was subsequently performed on formalin-fixed, paraffin-embedded tissue sections with antiosteopontin antibody (mouse, monoclonal, clone Km21, Santa Cruz iotechnology, Santa Cruz, C). citrate buffer microwave pretreatment was performed on unstained paraffin sections, and osteopontin antibody was applied at a 1:100 dilution using the DKO utostainer (DKO, Carpinteria, C). The detection system used was the DKO EnVision Plus Polymer System. The chromogen used was D Plus (DakoCytomation, Carpinteria, C). n epithelioid mesothelioma demonstrating robust staining with the osteopontin antibody was selected as a positive control sample for all runs, and negative control experiments were performed appropriately. Expression of osteopontin in malignant and reactive mesothelial cells was evaluated independently by 2 pathologists (D.T. and J..W.) using a semiquantitative scale denoting the extent of staining (percentage of the cells of interest that stain with osteopontin antibody). The scoring system applied was as follows: 0, no cells staining; 1, fewer than 25% of cells staining; 2, 25% to 50% of cells staining; and 3+, more than 50% of cells staining. For discrepancies, the cases were reexamined at a 2-headed scope, and the staining score was reached by consensus. Results The individual scoring of osteopontin expression and patient age and sex data are listed in Table 1. ll 7 mesotheliomas and 19 of 20 reactive mesothelial proliferations showed cytoplasmic osteopontin expression Table 2. Positive osteopontin staining was observed in a granular cytoplasmic pattern without membrane or Golgi accentuation. Nuclear staining was not observed. staining distribution of 2+ or greater was demonstrated by 7 (100%) of 7 mesotheliomas and 13 (65%) of 20 reactive mesothelial proliferations Table 3. In general, the intensity of the expression was subjectively greater in the malignant mesothelioma group Image 1 than in the reactive mesothelial group Image 2 and Image 3. Table 1 Clinical Data and Osteopontin Expression Scores * Case No./Sex/ge (y) Date of Procedure Score Mesothelioma cases 1/F/55 July 11, /M/74 March 29, /F/52 January 25, /M/66 February 3, /M/74 December 14, /M/78 January 6, /M/78 February 3, Reactive mesothelium cases 1/M/70 February 25, /M/82 September 19, /M/48 October 3, /M/78 November 26, /F/59 January 27, /F/36 October 3, /M/22 September 13, /M/16 pril 12, /M/23 October 19, /F/50 July 30, /M/20 January 11, /M/21 December 19, /M/25 December 27, /M/60 December 23, /F/14 June 20, /M/68 June 8, /M/60 December 23, /M/44 pril 26, /F/18 pril 11, /M/85 May 19, * The osteopontin scoring system was as follows: 0, no cells staining; 1+, <25% of cells staining; 2+, 25%-50% of cells staining; 3+, >50% of cells staining. Mean age, 68.1 years; men, 71%. Mean age, 45.0 years; males, 75%. m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN 581
3 Tigrani and Weydert / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS Table 2 Osteopontin Expression Reactive Mesothelium Malignant Mesothelioma Positive 19 7 Negative 1 0 Table 3 Extent of Osteopontin Expression Reactive Mesothelium Malignant Mesothelioma 2+ or or Discussion Osteopontin expression has been observed in a variety of tumors, and recently it has been shown that significantly higher serum osteopontin levels are present in patients with mesothelioma compared with patients without mesothelioma with previous asbestos exposure. 22 The implications of these findings are significant because they may provide a noninvasive means of surveillance for people with risk factors for mesothelioma. Likewise, if significant differences in the cellular expression of osteopontin exist between malignant and benign mesothelial proliferations, antiosteopontin immunohistochemical analysis may serve as an ancillary diagnostic tool in the differentiation Image 1 Morphologic () and paired immunohistochemical () staining in malignant mesothelioma., H&E (original magnification 67)., 3+ staining for osteopontin (original magnification 67). of malignant from benign mesothelial proliferations in biopsy material. In our study, we showed that osteopontin expression was not restricted to malignant mesothelial proliferations. ll 7 mesotheliomas stained with osteopontin antibody, and all but 1 case of reactive mesothelial proliferation showed some proportion of staining. Subjectively, the staining intensity appeared to Image 2 Morphologic () and paired immunohistochemical () staining in reactive mesothelial proliferations., H&E (original magnification 67)., 3+ staining for osteopontin (original magnification 67). Image 3 Morphologic () and paired immunohistochemical () staining in reactive mesothelial proliferations., H&E (original magnification 67)., 2+ staining for osteopontin (original magnification 67). 582 m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN
4 natomic Pathology / ORIGINL RTICLE be greater in the malignant mesothelial group than in the reactive mesothelial proliferation group. However, the presence of easily detectable expression of osteopontin in both groups does not support the use of this protein for determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations; however, a clear temporal relationship between the appearance of mesothelioma cancer cells and increasing levels of osteopontin has not been demonstrated. 23 Osteopontin may represent another tumor marker that has limited diagnostic usefulness in select clinical settings, similar to proteins such as C19-9 and α-fetoprotein (FP). C19-9 was initially a promising marker for pancreatic adenocarcinomas; however, the level was subsequently shown to be elevated in nonmalignant processes of the pancreas, including acute and chronic pancreatitis. 24 Similarly, the serum FP level is elevated in most hepatocellular carcinomas; however, the expression is quite variable and serum FP elevations occur in noncancer conditions such as hepatitis and cirrhosis. 25 Our study has important limitations. First, we studied a relatively small number of cases, and it is possible a larger data set may show significant differences in the expression of osteopontin between reactive and malignant mesothelial processes. Second, we chose not to quantitate the intensity of staining. Subjective determination of staining intensity is problematic because there is significant interobserver variability, and intensity varies with technique. If real differences in protein expression exist between reactive and malignant mesothelial proliferations, other studies will be needed to address this. Third, our immunohistochemical techniques and materials differed from those used by Pass et al. 22 We used a mouse monoclonal antibody from Santa Cruz iotechnology, whereas Pass et al 22 used a different clone supplied by Vector Laboratories (urlingame, C); the monoclonal antibody produced by Vector was no longer available at the time of our study. The 2 antibodies may recognize different epitopes of the osteopontin protein. In addition, our study used a different antigen-retrieval method, which may be more sensitive. 26 Finally, we stained whole tissue sections, whereas Pass et al 22 studied 2-mm cores of tissue. It is possible that some of our reactive mesothelial proliferation cases that showed partial staining for osteopontin would be interpreted as negative if smaller fragments of tissue were examined. lthough there may be some promise for the usefulness of serum osteopontin as a biomarker, use of the osteopontin antibody is not useful for distinguishing epithelioid mesotheliomas from reactive mesothelial proliferations. From the Department of Pathology, University of Iowa Carver College of Medicine, Iowa City. ddress reprint requests to Dr Weydert: 5239C RCP, 200 Hawkins Dr, Iowa City, I References 1. Churg, Cagle PT, Roggli VL. Tumors of the Serosal Membranes. Silver Spring, MD: RP Press; tlas of Tumor Pathology; Fourth Series, Fascicle Travis WD, rambilla E, Muller-Hermelink HK, et al, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IRC Press; World Health Organization Classification of Tumours. 3. Yaziji H, attifora H, arry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19: Cagle PT, Churg. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. rch Pathol Lab Med. 2005;129: Reinholt FP, Hultenby K, Oldberg, et al. Osteopontin: a possible anchor of osteoclasts to bone. Proc Natl cad Sci U S. 1990;87: accarini-contri M, Taparelli F, Pasquali-Ronchetti I. Osteopontin is a constitutive component of normal elastic fibers in human skin and aorta. Matrix iol. 1994;14: Weber GF, shkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271: Darling MR, Gauthier M, Jackson-oeters L, et al. Osteopontin expression in salivary gland tumours. Oral Oncol. 2006;42: Tuck, Hota C, Wilson SM, et al. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene. 2003;22: Rudland PS, Platt-Higgins, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62: Tuck, O Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. rch Pathol Lab Med. 1997;121: Tuck, Chambers F. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland iol Neoplasia. 2001;6: Thalmann GN, Sikes R, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999;5: Coppola D, Szabo M, oulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10: Tuck, O Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79: Chambers F, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer. 1996;15: Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001;171: m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN 583
5 Tigrani and Weydert / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS 18. Donati V, oldrini L, Dell Omodarme M, et al. Osteopontin expression and prognostic significance in non small cell lung cancer. Clin Cancer Res. 2005;11: grawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94: Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JM. 2002;287: Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79: Pass HI, Lott D, Lonardo F, et al. sbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353: Cullen MR. Serum osteopontin levels: is it time to screen asbestos-exposed workers for pleural mesothelioma [editorial]? N Engl J Med. 2005;353: Eskelinen MJ, Haglund UH. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg. 1999;165: loomer JR, Waldmann T, McIntire KR, et al. lphafetoprotein in nonneoplastic hepatic disorders. JM. 1975;233: Sabattini E, isgaard K, scani S, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research: critical comparison with the PP, ChemMate, CS, LC, and SC techniques. J Clin Pathol. 1998;51: m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationThe Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More information20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationCytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationNotice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
More informationRecommendations for the Reporting of Pleural Mesothelioma
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationUses and Abuses of Pathology in Asbestos-exposed Populations
Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationImmunohistochemistry on cytology specimens from pleural and peritoneal fluid
Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have
More informationBAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility
More informationCytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
More informationAcadémie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
More informationRare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationThe Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions Farnaz Hasteh, MD 1 ; Grace Y. Lin, MD, PhD 1 ; Noel Weidner, MD 1 ; and Claire
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationProduct Datasheet and Instructions for Use
Product Code: MP-378-CMK01 (0.1ml conc) MP-378-CMK05 (0.5ml conc) MP-378-PM6 (6ml RTU) Product Description: CD141 (Thrombomodulin) Concentrated and Prediluted Monoclonal Antibody Control Number: 901-378-071709
More informationHow To Diagnose And Treat A Tumour In An Effusion
Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura
More informationNo Difference Between Mesothelioma and Pulmonary and Nonpulmonary Adenocarcinoma DO NOT DUPLICATE. Malignancy is a common cause of effusions of the
NONGYNECOLOGIC CYTOPTHOLOGY CK5/6 in Effusions No Difference etween Mesothelioma and Pulmonary and Nonpulmonary denocarcinoma nnika Dejmek, M.D., Ph.D. Objective To test the performance of CK5/6 for the
More informationHow To Use Calretinin
Product Code: MP-092-CR01 (0.1ml concentrate) MP-092-CR05 (0.5ml concentrate) MP-092-CR1 (1ml concentrate) MP-092-PR6 (6ml RTU) Product Description: Calretinin Concentrated and Prediluted Polyclonal Antibody
More informationTitle: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)
More informationDistinguishing benign from malignant mesothelial
ORIGINAL ARTICLE IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations Anna F. Lee, MDCM, PhD,*w Allen M. Gown, MD,wz and Andrew Churg, MD*w Abstract:
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationIntraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas
International Urology and Nephrology 28 (1), pp. 73-77 (1996) Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas $. O. OZDAMAR,*
More information3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationMOC-31 Exhibits Superior Reactivity Compared With Ber-EP4 in Invasive Lobular and Ductal Carcinoma of the Breast. A Tissue Microarray Study
RESEARCH ARTICLE MOC-31 Exhibits Superior Reactivity Compared With Ber-EP4 in Invasive Lobular and Ductal Carcinoma of the Breast A Tissue Microarray Study Reetesh K. Pai, MD and Robert B. West, MD Abstract:
More informationToday s Topics. Tumors of the Peritoneum in Women
Today s Topics Tumors of the Peritoneum in Women Charles Zaloudek, M.D. Department of Pathology 505 Parnassus Ave., M563 University of California, San Francisco San Francisco, CA USA charles.zaloudek@ucsf.edu
More informationProtocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system
More informationCarbohydrate antigen 19 9 (CA 19 9) (serum, plasma)
Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Carbohydrate antigen 19 9 (CA 19 9) 1.2 Alternative names Cancer antigen 19 9, cancer antigen GI
More informationInformation Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports
Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports W. Scott Campbell, Ph.D., MBA James R. Campbell, MD Acknowledgements Steven H. Hinrichs, MD Chairman
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationMIB-1 and MCM-2 Immunohistochemical Analysis Does Not Aid in Identification of Serrated Colorectal Polyps With Abnormal Proliferation
Anatomic Pathology / MIB-1 AND MCM-2 AND SERRATED POLYPS MIB-1 and MCM-2 Immunohistochemical Analysis Does Not Aid in Identification of Serrated Colorectal Polyps With Abnormal Proliferation David Gray,
More informationCase based applications part III
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationEarly Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention
Early Detection Research Network: Validation Infrastructure Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention 15 October 2015 Mission The NCI Early Detection Research Network s (EDRN) mission is to implement
More informationLung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology
Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationImmunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium
& 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 1 Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium Ayuko Sato 1, Ikuko Torii
More informationMALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT
MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT Written by: Karyn Varley MS, SCT(ASCP) The donating laboratory would like to remain anonymous. PATIENT HISTORY 28 year old female Lived
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationTUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD Victor E. Reuter, MD Memorial Sloan-Kettering Cancer Center reuterv@mskcc.org 66 th Annual Pathology Seminar California Society of Pathologists Short
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationProtocol for the Examination of Specimens From Patients With Tumors of the Peritoneum
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationAdvances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
More informationHKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
More informationJ of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063
PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi
More informationPleural and Pericardial fluids a one year analysis
Pleural and Pericardial fluids a one year analysis Dr Olafsdottir Dr J Williams Department of Cytology, Llandough Hospital Contents Background Standards Aims/Questions Investigation group Results Conclusions
More informationImmunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin 16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationThe diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion
Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA
ISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA Yi-Ting Lin, 1 Bing-Shiun Wu, 2 Sheau-Fang Yang, 3 and Huang-Chi Chen 4 Departments of 1 Family Medicine, 2 Internal Medicine, and 3 Pathology,
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationBRIEF REPORTS. Introduction
BRIEF REPORTS WT1, Monoclonal CEA, TTF1, and CA125 Antibodies in the Differential Diagnosis of Lung, Breast, and Ovarian Adenocarcinomas in Serous Effusions Weijian Zhu, M.D., Ph.D. and Claire W. Michael,
More information510 (k) Summary DESCRIPTION OF DEVICE: Intended Use
510 (k) Summary Asymmetm, Inc. 117 Senate Brook Drive Arnston, CT 06231 (860) 716-8888 Contact Person: Maria McKeon Date Summary Prepared: February 4,2005 Name of Device: 1. ProprietaryITrade Name: Prostate-63
More informationBY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA
BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900
More informationCombined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma*
CHEST Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma* Jenette Creaney, PhD; Ivonne van Bruggen, BSc; Michelle Hof, BSc; Amanda Segal, MBBS; Arthur W. Musk, MBBS, MD, FCCP;
More informationIntroduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
More informationH istochem istry in the Diagnosis o f M alignant M esotheliom a *
A n n a l s o f C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, No. 3 Copyright 1973, Institute for Clinical Science H istochem istry in the Diagnosis o f M alignant M esotheliom a * MILTON
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationAbstract. Introduction. Material and Methods
Original Article Expression of Mesothelial Markers in Malignant Mesotheliomas: an Immunohistochemical Evaluation of 173 Cases I.N. Soomro, R. Oliveira*, J. Ronan, Z. R. Chaudry, J. Johnson Department of
More informationMalignant Mesothelioma in Body Fluids - with Special Reference to Differential Diagnosis from Metastatic Adenocarcinoma -
The Korean Journal of Pathology 2009; 43: 458-66 DOI: 10.4132/KoreanJPathol.2009.43.5.458 Malignant Mesothelioma in Body Fluids - with Special Reference to Differential Diagnosis from Metastatic Adenocarcinoma
More informationNovocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin) Product Code: NCL-L-CD141 Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle Upon Tyne NE12 8EW United Kingdom
More informationMaterials and Methods Specimens
The Expression Pattern of b-catenin in Mesothelial Proliferative Lesions and Its Diagnostic Utilities Yiran Dai, M.D., 1 * Carlos W.M. Bedrossian, M.D., FIAC, 2 and Claire W. Michael, M.D. 1 b-catenin
More informationPleural Mesothelioma: An Institutional Experience of 66 Cases
The Korean Journal of Pathology 2014; 48: 91-99 ORIGINAL ARTICLE Pleural Mesothelioma: An Institutional Experience of 66 Cases Soomin Ahn In Ho Choi Joungho Han Jhingook Kim 1 Myung-Ju Ahn 2 Departments
More informationDiseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours
Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationPathologist s Discussion of Plaintiffs Latest Theories
Pathologist s Discussion of Plaintiffs Latest Theories Mary Beth Beasley, MD Mt. Sinai Medical Center Annenberg Building 15th Floor Room 50 1468 Madison Avenue New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationIntroduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationFULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND
ChromoPlex 1 Dual Detection for BOND FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM View multiple antibodies on a single slide to deliver a comprehensive clinical result. 1 MULTIPLY YOUR CAPABILITIES
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationEp-CAM/Epithelial Specific Antigen (MOC-31)
Ep-CAM/Epithelial Specific Antigen (MOC- Product Identification Cat. No. Description 44588 EP-CAM 0,1 M (MOC- 44589 EP-CAM 1 M (MOC- 44283 EP-CAM RTU M (MOC- Symbol Definitions P C A E S DIL DOC# DIS ready-to-use
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationEffusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
More informationThe last decade has witnessed the dramatic coming
Lung Cancer Pathology Changing paradigm and priorities Ming-Sound Tsao, MD, FRCPC Abstract The last decade has witnessed the dramatic coming of age of targeted therapy in lung cancer. Several new targeted
More information